Predicting vaccine effectiveness in livestock populations: a theoretical framework applied to PRRS virus infections in pigs by Bitsouni, Vasiliki et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predicting vaccine effectiveness in livestock populations: a 2
theoretical framework applied to PRRS virus infections in 3 pigs
Citation for published version:
Bitsouni, V, Lycett, S, Opriessnig, T & Wilson, A 2019, 'Predicting vaccine effectiveness in livestock
populations: a 2 theoretical framework applied to PRRS virus infections in 3 pigs', PLoS ONE.
https://doi.org/10.1371/journal.pone.0220738
Digital Object Identifier (DOI):
10.1371/journal.pone.0220738
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
PLoS ONE
Publisher Rights Statement:
Copyright: © 2019 Bitsouni et al. This is an open access article distributed under the terms of the Creative
Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source
are credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 26. Sep. 2019
RESEARCH ARTICLE
Predicting vaccine effectiveness in livestock
populations: A theoretical framework applied
to PRRS virus infections in pigs
Vasiliki BitsouniID1*, Samantha LycettID1, Tanja Opriessnig1,2, Andrea Doeschl-Wilson1
1 The Roslin Institute and R(D)SVS, University of Edinburgh, Easter Bush Campus, Midlothian, Edinburgh,
Scotland, United Kingdom, 2 Department of Veterinary Diagnostic and Production Animal Medicine, College
of Veterinary Medicine, Iowa State University, Ames, Iowa, United States of America
* vbitsouni@gmail.com, Vasiliki.Bitsouni@roslin.ed.ac.uk
Abstract
Vaccines remain one of the main tools to control infectious diseases in domestic livestock.
Although a plethora of veterinary vaccines are on the market and routinely applied to protect
animals against infection with particular pathogens, the disease in question often continues
to persist, sometimes at high prevalence. The limited effectiveness of certain vaccines in
the field leaves open questions regarding the required properties that an effective vaccine
should have, as well as the most efficient vaccination strategy for achieving the intended
goal of vaccination programmes. To date a systematic approach for studying the combined
effects of different types of vaccines and vaccination strategies is lacking. In this paper, we
develop a theoretical framework for modelling the epidemiological consequences of vacci-
nation with imperfect vaccines of various types, administered using different strategies to
herds with different replacement rates and heterogeneity in vaccine responsiveness. Apply-
ing the model to the Porcine Reproductive and Respiratory Syndrome (PRRS), which
despite routine vaccination remains one of the most significant endemic swine diseases
worldwide, we then examine the influence of these diverse factors alone and in combination,
on within-herd virus transmission. We derive threshold conditions for preventing infection
invasion in the case of imperfect vaccines inducing limited sterilizing immunity. The model
developed in this study has practical implications for the development of vaccines and vacci-
nation programmes in livestock populations not only for PRRS, but also for other viral infec-
tions primarily transmitted by direct contact.
Introduction
For decades, vaccination has been considered the most powerful defense against a range of
infectious diseases. The major aims of veterinary vaccines are to improve the health of animals
and to prevent or reduce pathogen transmission, thereby mitigating the impact of infectious
diseases on livestock production in a cost-effective manner [1]. However, the potential of avail-
able vaccines to effectively control infectious diseases in livestock is contentious [2], because
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they often only confer limited sterilizing immunity and thus may not prevent infection, and
may only partly reduce pathogen transmission. A vaccine is considered effective if it can
reduce within-host pathogen burden as well as pathogen shedding, prevent or alleviate dis-
ease-induced clinical signs, and thus improve the general health conditions of exposed animals
[1]. More comprehensively, the desirable properties of an effective vaccine include: (i) high
safety (i.e. no reversion to virulence or disease caused by the vaccine strain) [3–5]; (ii) high
sterilizing immunity against a wide range of variant pathogen strains [6, 7]; (iii) fast onset of
protection [8]; (iv) high immunogenicity leading to reduction in pathogen load, shedding and
faster recovery [9], as well as (v) vaccine responsiveness in a broad range of hosts. Very few
vaccines on the market satisfy all of these properties. For example, vaccine safety is a major
concern for modified live vaccines [1, 10, 11], sterilizing immunity has been found to often
reach alarmingly low values [12], and heterogeneity in vaccine response, e.g. due to genetic or
age differences, seems ubiquitous [13–15].
All of these listed vaccine properties play an important role in pathogen transmission, and
thus in vaccine effectiveness on a population level. For example, sterilizing immunity affects
the susceptibility of a host to infection with a heterologous strain, whereas the impact of a vac-
cine on pathogen shedding affects an individual’s infectivity, i.e. its ability to transmit infection
to others [16]. Vaccines that accelerate host recovery reduce pathogen transmission by reduc-
ing the infectious period of a host [16–18]. In contrast, delay in onset of protection or host het-
erogeneity in vaccine response limit the time or extent of effective vaccine coverage in a
population, thus enable continued pathogen transmission.
The effectiveness of a given vaccine in the field depends not only on the properties of the
vaccine itself, but also on how the vaccine is applied and what other biosecurity measures are
in place. For example, herd closure during a disease outbreak has been promoted as a highly
effective disease control strategy, whereas continuous influx of new susceptible, possibly non-
vaccinated individuals contributes to long term persistence of the disease in a herd [17, 19].
Common vaccination strategies for livestock diseases include prophylactic (also known as pre-
ventative) and reactive mass vaccination [20]. Prophylactic vaccination is applied prior to
introduction of a pathogen into a herd, typically either as precaution to avoid recurrence of
previously resolved disease outbreaks in the herd or due to a perceived high risk occurring
from outbreaks in neighboring herds or farms. Although prophylactic mass vaccination is rare
in practice, it is considered the best strategy to prevent disease outbreaks and thus to minimize
the risk of a major epidemic [2]. Reactive vaccination on the other hand, although considered
less effective than prophylactic vaccination, is typically applied to control ongoing epidemics.
Application of either vaccination strategy is commonly hampered in practice by insufficient
vaccine availability, economic reasons or safety restrictions (e.g. clinical symptoms occurring
due to the vaccination) and logistic delays [20]. These affect the frequency and timing of vacci-
nation as well as the effective vaccine coverage in a population, i.e. the proportion of immu-
nized animals. One-off vaccination of a small proportion of animals in a herd with high
disease prevalence and high replacement rate may not be very effective, even if the applied vac-
cine contains all the desirable properties.
To the best of our knowledge, there is currently no theoretical framework to systematically
assess how different vaccine properties and vaccination strategies interactively influence infec-
tion invasion and transmission in herds with different demographics. This makes predictions
of vaccine effectiveness in the field extremely difficult. In particular, an infectious disease for
which a comprehensive framework that combines the diverse factors compromising vaccine
effectiveness would be extremely useful, is the Porcine Reproductive and Respiratory Syn-
drome (PRRS), which is caused by the PRRS virus (PRRSv) [21, 22]. PRRS is one of the most
significant and costly swine diseases globally [23], with estimated costs per year over $ 650
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million in the United states [24] and almost 1.5b € in Europe [25]. Although the first PRRS
vaccine has become commercially available more than two decades ago and several PRRS vac-
cines have been widely used since, the prevalence of PRRS remains high [26]. Failed vaccina-
tion programmes have raised an urgent demand for more effective vaccines [27, 28]. As PRRS
continues to spread rapidly all over the world, with more virulent PRRSv strains emerging in
Asia a few years ago, concerns have been raised about the epidemiological consequences of
vaccination and the evaluation of the vaccination effectiveness [29, 30].
The most common PRRS vaccines can be broadly categorised into modified-live virus
(MLV) vaccines or inactivated or killed virus (KV) vaccines. However, so far none of them has
been fully effective in preventing the spread of the virus within a herd [8, 21, 22, 26, 31, 32].
PRRS MLV vaccines are attenuated live vaccines, which have shown delayed but effective pro-
tection against homologous and some heterologous PRRSv strains [8]. They reduce clinical
signs, severity and the duration of viraemia and virus shedding [31, 33]. However, their limited
sterilizing immunity and immunogenicity to many circulating PRRSv strains have raised
major concerns regarding vaccine effectiveness [8, 21, 34–37]. PRRS KV vaccines, containing
adjuvants, on the other hand are known for their high safety, but the sterilizing immunity that
they provide against either homologous or heterologous PRRSv strains is extremely limited,
and they often fail to significantly reduce clinical signs [38], viremia and duration of shedding
in naïve animals [39]. While KV vaccines have failed to elicit detectable antibodies and also
barely elicit cell-mediated immune (CMI) response in PRRSv-negative pigs (i.e. ineffective
prophylactic vaccination) [40], in PRRSv-positive pigs (reactive vaccination) they have been
reported to strengthen both types of immune responses to the infecting virus [40, 41], thus
speeding up of recovery and potentially also reducing infectivity of the pigs. For this reason,
PRRS KV vaccines have been recommended for use as therapeutic vaccines for PRRSv treat-
ment rather than for disease prevention [42].
Despite tremendous efforts over the last three decades to understand PRRS pathogenesis
and vaccinology, effective PRRS vaccines, possessing safety, broad sterilizing immunity and
high immunogenicity, are still lacking [26, 28]. Furthermore, relatively little is known how the
existing vaccines affect virus transmission in a herd, or how these could be most effectively
applied to prevent PRRS outbreaks or reduce their impact. Experimental or field studies test-
ing the impact of a vaccine on virus transmission are not only rare but are limited to a specific
vaccine type, a specific vaccination strategy, a specific challenge strain, and specific pig breeds
[43]. Mathematical models, on the other hand, have been proven powerful tools to assess the
combined effects of several interacting factors on virus transmission and to predict the out-
come of different types of vaccines or vaccination strategies (see e.g. [2, 44, 45] and other refer-
ences therein).
The aim of this study is to develop a theoretical framework for modelling the combined epi-
demiological consequences of different vaccination strategies and different vaccine properties
applied to domestic livestock populations with different replacement rates. Table 1 lists the key
factors known to compromise vaccine effectiveness that are considered in this study. Vaccine
safety is not included in this table as in this study we only consider safe vaccines, i.e. vaccines
that do not revert to virulence and cause disease by themselves.
The core model developed in this study is generic to represent infection dynamics in differ-
ent livestock populations and for different pathogen species. However, to investigate the epide-
miological consequences of vaccination, we parameterize the model to represent a herd of pigs
exposed to a PRRSv strain different to the vaccine strain, when vaccination utilizing different
types of vaccines (outlined in Table 1) is applied either prophylactically or reactively, at differ-
ent time points and different frequencies, in herds with different replacement rates. In particu-
lar, we use the model to derive threshold conditions for preventing infection invasion even for
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vaccines with low sterilizing immunity. The model derived in this study provides new insights
for vaccine development and application for combating PRRS and other diseases threatening
domestic livestock populations, caused by viral infections primarily transmitted by direct
contact.
Materials and methods
Modelling transmission dynamics in a vaccinated population
The generic deterministic epidemiological Susceptible-Infected-Recovered (SIR) model pre-
sented below models transmission of a wild-type strain of a particular pathogen in a commer-
cial herd where vaccination is applied.
For an epidemiological SIR model in a homogenous non-vaccinated herd, the transmission
dynamics is controlled by two model parameters, the transmission term β and the recovery
rate γ. The transmission term β, loosely called transmission rate, is defined as the product of
the average contact rate and the probability that virus transmission occurs between an infected
and a susceptible hosts upon contact. In this study a frequency-dependent transmission, where
the number of contacts is independent of population size, is assumed.
Vaccination introduces heterogeneity in a population, dividing the proportions of pigs into
susceptible non-vaccinated (SN), susceptible vaccinated (SV), infected non-vaccinated (IN),
infected vaccinated (IV), and recovered non-vaccinated (RN) and recovered vaccinated (RV).
All recovered hosts (vaccinated or not) are assumed to gain full immunity to the modelled
pathogen field strain. The model is illustrated in Fig 1 and represented by the following set of
ordinary differential equations
dSN
dt
¼ lN   bNNSNIN   bNVSNIV   mSN ; ð1aÞ
Table 1. A list of factors that compromise vaccine effectiveness incorporated in our model. Vaccine responsiveness and administration are both captured by the same
parameter, p, which is the vaccine effective coverage. An incomplete coverage is either due to the vaccine only being administrated to a proportion of pigs or because not
all vaccinated pigs have developed protective immunity. A detailed description of the model parameters is given in Table 2.
Factors Effect on epidemiological characteristics Model parameters
Vaccine properties
Vaccine-induced sterilizing immunity Reduced transmission through lower host susceptibility �s
Vaccine-induced reduction in pathogen shedding Reduced transmission through lower host infectivity �i
Vaccine-induced increase in recovery rate Speed up recovery rate of infected host �γ
Time delay in onset of immunity Period between vaccination and the onset of vaccine-induced immunity time-dependent �s,i,γ (t)
Effective coverage (responsiveness) Proportion of immunized pigs p
Vaccination strategies
Prophylactic/Reactive � Vaccination before/after first infection incident �s,i,γ
Time & frequency Continuous vaccination/One-off vaccination λN, λV
Effective coverage (administration) Proportion of pigs to which the vaccine is administered p
Pathogen biology
Pathogen virulence Pathogen controlled infection transmission potential R0
Herd demography & management
Replacement rate Rate at which vaccinated/non-vaccinated pigs are replaced (zero in closed herds) λN, λV, μ
� Note that prophylactic versus reactive vaccination strategies are mainly described by the initial conditions (ICs) of the system as given in the following section.
https://doi.org/10.1371/journal.pone.0220738.t001
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dSV
dt
¼ lV   bVNSVIN   bVVSVIV   mSV ; ð1bÞ
dIN
dt
¼ bNNSNIN þ bNVSNIV   ðgN þ d þ mÞIN ; ð1cÞ
dIV
dt
¼ bVNSVIN þ bVVSVIV   ðgV þ mÞIV ; ð1dÞ
dRN
dt
¼ gNIN   mRN ; ð1eÞ
dRV
dt
¼ gVIV   mRV ; ð1fÞ
with the initial conditions (ICs):
Sjð0Þ ¼ Sj0 � 0; Ijð0Þ ¼ Ij0 � 0; Rjð0Þ ¼ 0; j ¼ N;V; ð2Þ
where βjk, j, k = N, V, are the transmission rates from an infected pig of type k to a susceptible
pig of type j, γj are the recovery rates, λj are the corresponding birth/replacement rates and μ is
the average death/removal rate. Moreover, d is the mortality rate due to the infection, which is
assumed to be non-zero only for non-vaccinated infected pigs. Equal birth/replacement and
death/removal rates are assumed, which corresponds to a constant population size when the
death rate due to the infection is zero, i.e. λN + λV = μ. The values Sj0 and Ij0 are non-negative
real values denoting the initial proportion of susceptible and infected in population. Table 2
presents a list of all model parameters together with their assumed values for the simulations
in this study and corresponding information source. For the simulations it is assumed that the
infection with the field pathogen strain in a herd is introduced by a proportion of non-vacci-
nated, IN0 , and/or vaccinated, IV0 , individuals in an otherwise fully susceptible population. In
Fig 1. Flow diagrams of the heterogeneous vaccine SIR model given by (1).
https://doi.org/10.1371/journal.pone.0220738.g001
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prophylactic vaccination IN0 and IV0 can take values greater than or equal to zero, while in reac-
tive vaccination it is always IV0 ¼ 0.
The average number of secondary cases arising from one infection when the entire popula-
tion is susceptible, i.e. the basic reproductive ratio, denoted by R0 is given by the following Eq
[46]
R0≔
lNbNN
mðgN þ d þ mÞ
þ
lVbVV
mðgV þ mÞ
: ð3Þ
R0 is a key epidemiological measure for how “infectious” a disease is, with large R0 possibly
representing more virulent pathogen strains [47]. Vaccination ultimately aims to prevent the
invasion of an infection into a population, which corresponds to reducing R0 to below one
(R0 < 1).
One of the factors that compromise vaccine effectiveness is the effective vaccine coverage,
p, which may capture the proportion of herd members to which the vaccine has been applied
or the proportion of herd members that respond to the vaccine, i.e. are effectively immunized
(see Table 1). Vaccine coverage p is implemented into the model through the replacement
rates.
lN ¼ ð1   pÞm and lV ¼ pm; 0 � p < 1: ð4Þ
Therefore, for 0� p� 1 the basic reproductive ratio in a population with effective vaccine
coverage p becomes
R0 ¼
ð1   pÞbNN
ðgN þ d þ mÞ
þ
pbVV
ðgV þ mÞ
¼ ð1   pÞRN
0
þ pRV
0
; ð5Þ
where RN
0
and RV
0
the basic reproductive ratios in non-vaccinated and vaccinated pigs, respec-
tively. In the case of no removal or replacement, the basic reproductive ratio of the closed herd
is
R0 ¼
ð1   pÞbNN
ðgN þ dÞ
þ
pbVV
gV
: ð6Þ
Table 2. Description of the model parameters together with their assumed value ranges considered in this study.
Param. Description Value Reference
λN Replacment rate of non-vaccinated susceptible pigs 0 − 0.0017 [48–50]
λV Replacment rate of vaccinated susceptible pigs 0 − 0.0017 [48–50]
βNN Transmission rate between non-vaccinated pigs 0.030 − 0.426 [43, 49, 51, 52]
βNV, βVN Transmission rates between vac. and non-vac. pigs 0 − 0.426 Estimated by relations (7a) & (8a)
βVV Transmission rate between vaccinated pigs 0 − 0.426 Estimated by relations (7a) & (8b) (see also Ref. [43, 52])
γN Recovery rate of non-vaccinated pigs 0.004 − 0.1428 [43, 49, 50]
γV Recovery rate of vaccinated pigs 0.0057 − 0.1 Estimated by relation (9) (see also Ref. [43, 49, 53, 54])
μ Death/removal rate 0 − 0.037 [43, 49, 51, 52]
d Death rate due to infection 0 − 0.001 Estimated
RN
0
Basic reproductive ratio of non-vaccinated pigs 1 − 9.04 [43, 49, 52, 55]
RV
0
Basic reproductive ratio of vaccinated pigs 0 − 7.1 Estimated by relations (3) & (7)–(9) (see also Ref. [43, 49, 52])
https://doi.org/10.1371/journal.pone.0220738.t002
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Vaccine properties
To investigate vaccine effectiveness, we distinguish between different types of vaccines and dif-
ferent vaccination strategies (see Fig 2). In particular, we investigate how the diverse factors
compromising vaccine effectiveness, in addition to effective vaccine coverage, listed in Table 1
separately and combined affect the infection invasion and spread in the herd. Vaccine proper-
ties either affect the transmission rates βjk or the recovery rates γj, j, k = N, V, in the epidemio-
logical model (1). Transmission rates may be reduced by the vaccine in two ways, i.e. either
due to a reduction in host susceptibility, modelled by the vaccine’s sterilizing immunity �s, or
due to a reduction in host infectivity, modelled by a vaccine-induced effect �i on the transmis-
sion rate. Note that these effects may refer to two different mechanisms. For example vaccine-
induced reduction in host susceptibility may refer to mechanisms reducing pathogen entry
and establishment into the target cells, whereas vaccine-induced reduction in host infectivity
may refer to mechanisms regulating pathogen replication and shedding. Similarly, a vaccine
may trigger immune mechanisms that speed up recovery. Thus, we also model here the vac-
cine-induced effect on the recovery rate denoted by �γ.
Assuming that these vaccine properties act independently from each other (i.e. multiplica-
tive effects on the model parameters), the different vaccine properties are represented in the
model (1) as follows:
1. Vaccine-induced sterilizing immunity �s(0� �s� 1): In this case the vaccine reduces the sus-
ceptibility of the vaccinated individual with the following effects on the transmission rates
bVN ¼ ð1   �sÞbNN; ð7aÞ
bVV ¼ ð1   �sÞbNV : ð7bÞ
2. Vaccine-induced reduction in host infectivity �i(0� �i� 1): In this case the vaccine reduces
the propensity of a vaccinated infected host to transmit infection to a susceptible host upon
contact, which is represented by
bNV ¼ ð1   �iÞbNN ; ð8aÞ
bVV ¼ ð1   �iÞbVN: ð8bÞ
Fig 2. Tree diagram showing modelled scenarios. We refer to the text for definitions of the parameters and further explanations. Here, the vaccine coverage p
represents either the proportion of individuals to which the vaccine is administered or the proportion of vaccine responders. Also, delay in the onset of vaccine induced
immunity is not explicitly included as vaccine property, as it is equivalent to modelling a reactive vaccination strategy.
https://doi.org/10.1371/journal.pone.0220738.g002
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3. Vaccine-induced increase in recovery rate �γ(0 < �γ� 1): This is modelled by
gV ¼ gN=ð1   �gÞ: ð9Þ
4. Delay in the onset of vaccine-induced immunity: The delay in the onset of vaccine-induced
immunity is incorporated in the model by changing the constants �s, �i and �γ to step func-
tions �s(t), �i(t) and �γ(t) with
�s;i;g tð Þ≔
0; for 0 � t < t0;
�s;i;g; for t � t0;
8
<
:
ð10Þ
where t0 denotes the time period between vaccination and the onset of vaccine-induced
immunity. As outlined below, these step functions are also used to model reactive vaccina-
tion. Finally, it should be noted that the limiting cases γV!1 and βjk = 0 in Eqs (7)–(9)
represent full protection of the vaccine and prevention of pathogen transmission when vac-
cination is applied, respectively.
Vaccination strategies
In this study we distinguish between two types of vaccination strategies, i.e. prophylactic and
reactive vaccination. In the case of prophylactic vaccination we assume that a proportion p of
the herd has been effectively vaccinated at the time of exposure to the field pathogen strain.
The initial conditions for this case are
SNð0Þ ¼ ð1   pÞð1   I0Þ; INð0Þ ¼ ð1   pÞI0;RNð0Þ ¼ 0; ð11aÞ
SVð0Þ ¼ pð1   I0Þ; IVð0Þ ¼ pI0;RVð0Þ ¼ 0; ð11bÞ
where I0 > 0 the total proportion of individuals (vaccinated and non-vaccinated) infected with
the field pathogen strain. Thus in the case of full vaccine coverage SN(0) = IN(0) = RN(0) = 0.
Reactive vaccination refers to the situation when vaccination is applied only after a propor-
tion of non-immunized individuals has become infected either due to delayed vaccination or a
delayed onset of vaccine-induced immunization. It is modelled by the step functions (10),
describing the effect of vaccination on transmission and recovery rates once the vaccination is
applied at the time point t0 > 0.
Besides the two vaccination strategies, which mainly specify the proportion of vaccinated
individuals in a specific period, another factor that controls transmission dynamics within a
herd included in the model is the frequency of vaccination, and in particular whether vaccina-
tion is applied continuously or only once (hereafter denoted as one-off vaccination). In an
open herd with constant replacement of removed or dead individuals, continuous versus one-
off vaccination affect the replacement rates λN and λV as follows:
1. Continuous vaccination in an open herd: In this case we assume a continuous vaccination of
incomers, with constant vaccine coverage p, i.e. λN = (1 − p)μ, λV = pμ.
2. One-off vaccination in an open herd: In this case we assume that vaccination is not applied
to incoming animals, i.e. λN = μ, λV = 0.
In a closed herd, vaccination is assumed to be applied only once, and in this case the replace-
ment rates λN and λV are zero, i.e. there are no incomers. In summary, different vaccination
frequencies in open or closed herds can be modelled through different replacement rates.
Predicting vaccine effectiveness in livestock populations
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Fig 2 illustrates the different scenarios corresponding to different vaccine properties and
vaccination strategies modelled in this study.
Application to PRRS
The model presented in Eqs (1) and (2) above can be applied to model PRRSv transmission
dynamics in pig herds under different vaccination scenario [48, 49, 51]. Values of the model
parameters were obtained from the literature (see references listed in Table 2). The large value
range for these may represent the large variety in existing PRRSv strains (e.g. low or highly vir-
ulent strains), types of pig herds (e.g. breeding herds vs growing pigs, multi-site or single-site
production), environments and management structures, etc. This large range in values for epi-
demiological parameters leads to a range of R0 values between one and nine in non-vaccinated
herds (Table 2) and thus allows assessment of vaccine and vaccination effects under a wide
range of conditions. We therefore present results for relatively low and high R0 values R0� 2
and R0� 6, respectively.
In each simulated scenario, the infection in a herd is introduced by assuming 0.1% of
the pigs are infected at the beginning of the observation period. Depending on the model sce-
nario, these are either vaccinated (prophylactic vaccination) or non-vaccinated (reactive
vaccination).
To assess vaccine effectiveness we focus on three important epidemiological measures [45]
(i) the risk of infection invasion (or infection eradication if already invaded), represented by
R0; (ii) the peak prevalence of infection; (iii) the time at which the peak prevalence occurs.
Table 2 lists the parameter value ranges used in the simulations together with the literature
source. Here we show results for two different average values of RN
0
, i.e. RN
0
¼ 2 and 6 [43, 49,
52, 55], representing a moderate and a severe PRRS epidemic, respectively. These values were
produced by assuming an average duration of the infectious period of 56 days [49, 55, 56], cor-
responding to a recovery rate for non-vaccinated pigs of γN = 0.01785 per day. The assumed
transmission rate corresponding to RN
0
¼ 2 was βNN = 0.04 per day, whereas the transmission
rate corresponding to RN
0
¼ 6 was βNN = 0.12 per day. Choosing different parameters sets of
βNN, γN can lead to the same RN0 values, generalising a bit the results and giving a good theoreti-
cal framework, since presenting all the possible sets is not possible.
Results
1 Prophylactic vaccination
1.1 Continuous vaccination. To quantify the effect of a vaccine on infection invasion in a
herd we use relation (5), which becomes
R0 ¼
ð1   pÞbNN
ðgN þ d þ mÞ
þ
pð1   �sÞð1   �iÞbNN
gN
1  �g
þ m
� � : ð12Þ
Assuming negligible infection induced death rate d (see Table 2), Eq (12) simplifies to:
R0 � ½ð1   pÞ þ pð1   �sÞð1   �iÞð1   �gÞ�RN0 : ð13Þ
Relation (13) shows that the vaccine properties �s, �i and �γ exhibit an equivalent effect on R0.
Because of the assumed independence between these vaccine properties (Eqs (7)–(9)), different
effects of a vaccine act multiplicatively on R0. Thus, assuming vaccine coverage of one (p = 1),
a vaccine providing 50% sterilizing immunity (�s = 0.5), but having no effect on the infectivity
or recovery rate of individuals, reduces the R0 by approximately 50%. A vaccine that in addi-
tion to a 50% sterilizing immunity also reduces infectivity or speeds up recovery by 50%, leads
Predicting vaccine effectiveness in livestock populations
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to 75% reduction in R0, whereas vaccines that have a beneficial effect on all three host traits
susceptibility, infectivity and recovery, reduces R0 by 88.5%. This symmetry is also illustrated
in Fig 3A and 3B, which shows a surface plot (panel A) and a contour plot (panel B) of the
dependence of R0 on vaccine-induced sterilizing immunity, �s, and vaccine-induced effects on
infectivity, �i, and recovery, �γ, respectively, for vaccine coverage p = 1. The coloured surface/
curves correspond to the threshold R0 = 1 in Eq (12), between scenarios in which the infection
is expected to invade (R0 > 1; area below the threshold) or not invade (R0 < 1; are above the
threshold) a herd. The graphs show that even for large RN
0
(e.g. virulent PRRSv strains), one of
the investigated vaccine properties alone can prevent the infection invasion if the effect size is
sufficiently large (e.g. �s,i� 0.84 or �γ� 0.85 for RN0 ¼ 6). However, considerably less sterilizing
immunity or reduction in infectivity are required, if the vaccine also simultaneously speeds up
recovery (e.g. �s,i� 0.5 is sufficient if �γ = 0.7).
Fig 3. The dependence of R0 on the vaccine-induced sterilizing immunity, �s, vaccine-induced reduction in host
infectivity, �i, vaccine-induced increase in recovery rate, �γ, and vaccine coverage, p. A. 3D surface plot
corresponding to R0 = 1 in Eq (12), for a high average transmission potential (RN0 ¼ 6) and full immunization coverage
(p = 1). B. 2D contour plot showing the dependence of R0 on �i and �γ, for different values of �s and p = 1. C. 3D surface
plot corresponding to R0 = 1 in Eq (12), for a high average transmission potential (RN0 ¼ 6) and �i = 0.5. D. 2D contour
plot showing the dependence of R0 on the effective vaccine coverage, p, and �γ, for different values of �s and �i = 0.5.
The coloured continuous curves in 2D plots correspond to R0 = 1 in Eq (12) for a high average transmission potential
(RN
0
¼ 6) and dotted curves correspond to R0 = 1 for a low virulent PRRSv strain (RN0 ¼ 2). Areas above these curves
correspond to R0 < 1 where the infection cannot invade the herd. Here d = 0.001, μ = 0.0017. The transmission and
recovery rates are values within the ranges given in Table 2, that satisfy RN
0
¼ 6 and RN
0
¼ 2 for the continuous and
dotted curves, respectively.
https://doi.org/10.1371/journal.pone.0220738.g003
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Fig 3C and 3D show equivalent plots for incomplete vaccine coverage. The graphs demon-
strate that infection invasion can be prevented even if the vaccine offers low or zero vaccine-
induced sterilizing immunity, given sufficiently high vaccine coverage and vaccine-induced
effect on host infectivity or recovery. For the plots in Fig 3C and 3D it was assumed that �i =
0.5, i.e. the vaccine reduces host infectivity by 50%. For lower values of �i higher levels of effec-
tive coverage or/and vaccine-induced increase in recovery rate would be needed to prevent
infection invasion for given levels of sterilizing immunity. Only when the vaccine is fully pro-
tective (i.e. any of �s,i,γ = 1) the required vaccine effective coverage no longer depends on the
other vaccine effects, but only on the RN
0
value in the equivalent non-vaccinated population
(see gold continuous and dotted lines in Fig 3B). For example, for RN
0
¼ 2, vaccination with a
fully protective vaccine would require at least 49% vaccine coverage, whereas 83% coverage
would be required for RN
0
¼ 6 (Fig 3D).
In contrast to the near symmetric effect of the different vaccine properties, represented by
�s,i,γ, on R0, their effect on the infection dynamics can be diverse. Both vaccine-induced steriliz-
ing immunity and vaccine-induced reduction in host infectivity have a symmetric effect on the
transmission rate (Eqs (7) and (8)). However, Fig 4 shows that the effects of �s and �i, on the
infection dynamics are different to those corresponding to �γ. Higher vaccine-induced steriliz-
ing immunity, �s, or greater reduction in infectivity, �i, (not shown here) leads to milder, but
prolonged epidemics due to the slower rate at which infection is transmitted, causing also a
later occurrence of the first infection incidence and peak prevalence, and a slower rate of post-
peak prevalence decline (Fig 4A). In contrast, vaccine-induced increase in recovery rate, �γ,
mainly affects peak prevalence, but not the timing at which it occurs or the rate of decline (Fig
4C). For continuous prophylactic vaccination, vaccine-induced effects on transmission or
recovery rates also affect the long-term steady-state prevalence of infection. Higher vaccine-
induced effect on transmission or recovery rate leads to a greater reduction of the long-term
endemic steady state. For example a 50% vaccine-induced sterilizing immunity, �s (or 50% vac-
cine-induced reduction in host infectivity, �i), will reduce the endemic steady state of the
infected animals by 25%, while a 50% vaccine-induced increase in recovery rate will reduce the
endemic steady state of the infected animals by 59%. As would be expected, multiple vaccine
properties combined affect both the timing and level of peak infection prevalence, and the rate
of decline (Fig 4E). The infection dynamics also confirm the results shown in Fig 3A and 3B,
that an 85% of susceptibility, infectivity or recovery alone (Fig 4A and 4C) or a 50% combined
effect of all (Fig 4E) is required to prevent infection from invading a herd.
1.2 One-off vaccination. One-off vaccination in an open herd with constant replacement
rate implies that λV = 0 and thus does not reduce the basic reproductive ratio, i.e. R0 ¼ RN0 (see
relation (3)). This is due to the immediate influx of non-vaccinated pigs into the herd. If there
is a continuous influx of non-vaccinated pigs into the herd, one-off vaccination is not adequate
for preventing infection invasion. However, as shown in Fig 4 (right column), vaccination can
substantially reduce the severity of the epidemic. For example, in the simulations of Fig 4, a
50% vaccine effect on susceptibility, infectivity and recovery can reduce the peak prevalence
up to 57.1% (Fig 4F). Moreover, the greater the effect of a vaccine on host susceptibility or
infectivity, the later the occurrence of peak prevalence (Fig 4B). Comparison of the continuous
(left-column) with the one-off (right-column) prophylactic vaccination shows that the short-
term effects are very similar in both cases (Fig 4). In contrast, whereas in the one-off vaccina-
tion scenario, the endemic steady state is not affected by vaccination (i.e. the endemic steady
state is the same for every value of 0� �s,i,γ< 1; Fig 4B, 4D and 4F), continuous vaccination
alters the endemic steady state values, whereby more effective vaccines (i.e. greater values of
�s,i,γ; Fig 4A, 4C and 4E) correspond to lower prevalence in the long-term.
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Fig 4. The effect of prophylactic mass vaccination for different � = �s,i,γ values on the infection dynamics for
continuous vaccination, i.e. λN = 0, λV = 0.0017 (left column), and one-off vaccination, i.e. λN = 0.0017, λV = 0
(right column). A.-B. The vaccine only affects host susceptibility, i.e. sterilizing immunity � = �s, �γ = �i = 0 (see
relation (7)); C.-D. The vaccine only affects recovery rate, i.e. � = �γ, �s = �i = 0 (see relation (9)); E.-F. The vaccine
equally affects host susceptibility, infectivity and recovery rate, � = �s,i,γ (see relations (7)–(9)). Other chosen parameter
values were βNN = 0.12, γN = 0.01785, d = 0.001, μ = 0.0017, and the initial conditions are SV (0) = 0.999, IV (0) = 0.001
(see relation (11) for p = 1 and I0 = 0.001).
https://doi.org/10.1371/journal.pone.0220738.g004
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1.3 Closed herd. Based on relation (6), the effect of vaccination on infection invasion (or
eradication if already invaded) in a closed herd is given by
R0 ¼
ð1   pÞbNN
ðgN þ dÞ
þ
pð1   �sÞð1   �iÞbNN
gN
1  �g
� � ð14Þ
which is the same as R0 for the continuous vaccination of a herd with replacement when μ = 0
(see Eq (12)). Therefore, the vaccine properties, �s,i,γ, will have a similar effect on preventing an
infection to invade a herd as the continuous vaccination in an open herd. This can be easily
seen by comparing the left columns of Figs 4 and 5 (prophylactic vaccination in a closed herd).
In other words, even for severe epidemics in non-vaccinated herds with corresponding
RN
0
¼ 6, a vaccine with sufficiently strong effect on either host susceptibility, infectivity or
recovery can prevent infection invasion (e.g. �s,i,γ� 0.852 for RN0 ¼ 6), and this can also be
achieved by a combination of effects with weaker effect size (e.g. �s = �i = �γ = 0.5 for RN0 ¼ 6).
The main difference of a closed herd compared to an open herd is that in a closed herd, the
R0 value corresponding to the same values for the epidemiological model parameters (βjk, γj, j,
k = N, V and d) is greater and thus the infection invasion is more likely. This implies that for a
closed herd, vaccine requirements for preventing the invasion of infections are stricter than
for open herds. Differences in the infection dynamics between open and closed herds occur
mainly in the long term, where the infection dies out in closed herds, regardless of whether or
not vaccination is applied, whereas it reaches an endemic equilibrium in open herds (Figs 4
and 5 and [17]).
2 Reactive Vaccination
In modelling terms, reactive vaccination is equivalent to applying prophylactic vaccination
with delayed onset of immunity at a stage where infection invades a herd before the full vac-
cine-induced immunization effects have been reached. Thus, although these types of vaccina-
tion cannot prevent the infection from invading, they can still reduce the prevalence of
infection and may ultimately eliminate the infection from a herd. Fig 6 shows prevalence pro-
files resulting from reactive vaccination in a herd with replacement, either applied continu-
ously (left column) or one-off (right column). Overall, the vaccine effects on the infection
dynamics are similar to those observed for the corresponding prophylactic vaccinations (see
Fig 4), with continuous vaccination leading to a long-term reduction in the prevalence of
infection and one-off vaccination only affecting infection prevalence in the short-term, but
reaching the same endemic equilibrium as that corresponding to the equivalent non-vacci-
nated herd (Fig 6). Reactive vaccination, even if applied as a one-off disease control, can sub-
stantially reduce peak prevalence. In fact, prevalence profiles corresponding to reactive
vaccination applied prior to the time of peak prevalence, look remarkably similar to those cor-
responding to prophylactic vaccination with the same vaccine, although prevalence generally
reaches its peak slightly later in the prophylactic vaccination scenario (Fig 6A–6F). Moreover,
reactive vaccination, when applied continuously can eliminate infection in a herd, under the
same required vaccine properties as for prophylactic vaccination, regardless of when it is
applied (Fig 6E). For example, Fig 6E shows a scenario where the infection can be eliminated
from a herd when reactive vaccination inducing 50% combined vaccine effect on transmission
and recovery rate is applied. The timing of the reactive vaccination affects primarily peak prev-
alence and total number of infectees (early vaccination corresponds to lower the peak preva-
lence and less infectees), rather than whether and when the infection is eliminated from the
herd (Fig 6).
Predicting vaccine effectiveness in livestock populations
PLOS ONE | https://doi.org/10.1371/journal.pone.0220738 August 30, 2019 13 / 23
Fig 5. The effect of fully effective mass vaccination (i.e. p = 1 at the time of vaccination) with vaccines of different
properties on the infection dynamics in the case of prophylactic (left column) and reactive (right column)
vaccination in a closed herd. Profiles of different colours correspond to different � = �s,i,γ values on the infection
dynamics (left column; see caption in Fig 4), or different times when vaccination is applied (right column; see caption in
Fig 6). A.-B. The vaccine only affects host susceptibility, i.e. sterilizing immunity, but no effect on infectivity or recovery
Predicting vaccine effectiveness in livestock populations
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Somewhat surprisingly, Fig 6B and 6F indicate a slightly higher peak prevalence in the case
of one-off prophylactic mass vaccination compared to one-off reactive mass vaccination when
applied early in the epidemics. This is because the time and level of peak prevalence partly
depends on the relative proportion of infected animals when the vaccination is applied and the
proportion of new non-vaccinated incomers. At the time when prophylactic vaccination is
applied the initial proportion of infected vaccinated animals is very low and infection can only
spread slowly initially. However, prevalence rises relatively quickly as the non-vaccinated ani-
mals become infected and start to transmit the infection. In contrast, at the time when reactive
vaccination is applied (e.g. at 1/4 of peak prevalence time) all infected non-vaccinated animals
become vaccinated with lower transmission rate (assuming �i> 0), so that the proportion of
new non-vaccinated incomers will not face many highly infectious animals in the herd. Thus,
this case illustrates that a one-off reactive vaccination applied at the right time of an ongoing
epidemic can be more effective than the one-off prophylactic vaccination.
Fig 5 shows that in a closed herd the vaccine properties, �s,i,γ, will have a similar effect on
eradicating an infection as the continuous reactive vaccination in an open herd (see left col-
umn in Fig 6). Similar to the prophylactic vaccination, the main difference of a closed herd to
an open herd is that the infection will eventually die out in all vaccination scenarios (even
without vaccination) in a closed herd.
Discussion and conclusion
Imperfect vaccines that do not prevent infection transmission and heterogeneous response to
vaccines are common in livestock production and threaten the success of vaccination pro-
grams [57–59]. It is well known that the success of vaccination programs depends on the effec-
tive vaccination coverage as well as on the type of vaccine (e.g. [60]). However, vaccination
programs differ not only in these components, but also in when and how a particular vaccine
is applied as a single control measure or in combination with others such as herd closure. Yet,
to date relatively little is known how these factors interact with each other and affect the out-
come of vaccination programs. The epidemiological model developed in this study provides
for the first time detailed quantitative understanding of the relationship between these diverse
factors and disease invasion and spread in domestic livestock. The model predicts within-herd
infection dynamics in livestock populations following the application of imperfect vaccines,
and provides threshold conditions for vaccine properties and vaccination strategies to prevent
infection invasion or eliminate infection from a herd after infection invasion. This model was
parameterised and applied to PRRS as one of the major livestock examples where imperfect
vaccines are commonly applied and much debated in the scientific literature [8, 25, 26].
Most previous modelling studies have mainly focused on differences in vaccine efficacy
captured by reduction in β. Vaccine efficacy is however multi-faceted and most vaccines
reduce pathogen transmission not only by offering sterling immunity, but also by reducing
host infectivity and duration of infection. We therefore distinguished between multiple effects
in our model and we found that a vaccine can deviate substantially from perfect in one or all of
these properties, as long as they reduce pathogen transmission in several ways. For instance for
disease with an average transmission potential of R0 = 6 in a non-vaccinated herd, we found
that vaccines that reduce susceptibility, infectivity and recovery rate by 50% could prevent
(see Eqs (7) and (10)); C.-D. The vaccine only speeds up recovery, but offers no protection from infection and no
reduction in infectivity (see Eqs (9) and (10)); E.-F. The vaccine equally affects host susceptibility, infectivity and
recovery rate (see Eqs (7)–(9) and (10)). Here βNN = 0.12, γN = 0.01785, p = 1, d = 0.001, μ = λN,V = 0, and the initial
conditions are SV (0) = 0.999, IV (0) = 0.001 (left column) and SN (0) = 0.999, IN (0) = 0.001 (right column).
https://doi.org/10.1371/journal.pone.0220738.g005
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Fig 6. The effect of complete mass vaccination (i.e. p = 1) with vaccines of different properties on the infection
dynamics in the case of continuous (left column) and one-off (right column) reactive vaccination. Profiles of
different colours correspond to different times when vaccination is applied, i.e. (i) at the start of the epidemic,
equivalent to prophylactic vaccination (red continuous curves), (ii) at one quarter of the time of peak prevalence (green
dotted curves), (iii) at one half of the time of peak prevalence (blue dotted curves), (iv) at the time of peak prevalence
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infection invasion or eradication invaded infection. Moreover, our model revealed that imper-
fect vaccines, that only offer partial protection from infection with a heterologous virus strain,
can substantially reduce pathogen transmission and infection risk and prevalence in herds,
when applied as prophylactic strategy. Unsurprisingly, our model predicts that prophylactic
mass vaccination with a vaccine that confers high sterilizing immunity in all individuals is the
most effective strategy for preventing infection in a herd or for reducing prevalence. However,
our model also shows that even vaccines that offer no or little sterilizing immunity or only pro-
vide partial effective coverage can prevent infection invasion into a herd if the vaccine simulta-
neously reduces host infectivity e.g. by reducing pathogen shedding or speeding up recovery
time. In this case the occurrence of secondary infection cases can be successfully prevented, as
indicated by a reduction of the basic reproductive ratio of the vaccinated herd to values below
1. The results are relevant to certain MLV vaccines showing low sterilizing immunity [8, 21,
26, 31, 32], but significant reduction in viral shedding and infectious period. The model results
suggest that these vaccines, despite far from perfect, could achieve drastic reduction in the
occurrence and severity of PRRS outbreaks in commercial pig populations, and even help to
eliminate the disease.
As herd closure is a common control measure, a vaccination strategy considering a closed
herd was studied. According to our model results, similar levels of reduction in infection peak
prevalence can be achieved with one-off vaccination in closed herds as with continuous vacci-
nation of herds with constant replacement rate, for the same type of vaccine. However, when
prophylactic vaccination is applied in herds with constant influx of new animals, infection pre-
vention can only be achieved through continuous vaccination. One-off vaccination may be
used to delay and reduce peak prevalence, but cannot reduce long-term prevalence and hence
eliminate the infection from the herd.
Both, prophylactic and reactive vaccination are routinely applied to control PRRS in pig
farms [25, 61]. Reactive vaccination in particular is commonly used in farms where the virus
has been found endemic [8, 26]. Our model results indicate that the timing of vaccination is
crucial for achieving effective reduction in the prevalence of infection, whereas the frequency
of vaccination controls the chance of eliminating the infection from a herd. Indeed, reactive
vaccination campaigns are racing against the timeline in which the infection spreads within a
herd, and timely distribution of vaccines in response to an ongoing epidemic can prevent new
infection cases [20, 62, 63]. In our model, continuous reactive vaccination with a vaccine that
has combined positive effects on host transmission and recovery rates could eliminate the
infection from a herd even for high average transmission potential characterized by high RN
0
in
non-vaccinated populations. As PRRS KV vaccines are known to elicit immune responses to
the infecting virus in PRRSv-positive pigs (reactive vaccination) [40, 41], and offer low steriliz-
ing immunity in PRRSv-negative pigs, they are often not considered as effective vaccines for
disease prevention (i.e. PRRS KV vaccines are no longer available in the United States since
2005 [8]), but might exert a potential role as a therapeutic vaccine for PRRSV treatment [8,
26]. However, immune studies have shown further that KV vaccines can reduce pathogen
shedding in seropositive animals, hence host infectivity, and speed up recovery [42]. In line
(red dotted curves), (v) at double the time until peak prevalence (gold dotted curves) and when (vi) vaccination is not
applied at all (black continuous curves). A.-B. The vaccine only affects host susceptibility, i.e. sterilizing immunity, but
no effect on infectivity or recovery (�s = 0.5, �γ = �i = 0) (see relations (7) and (10)); C.-D. The vaccine only speeds up
recovery, but offers no protection from infection and no reduction in infectivity (�γ = 0.5, �s = �i = 0) (see Eqs (9) and
(10)); E.-F. The vaccine equally affects host susceptibility, infectivity and recovery rate, � = �s,i,γ = 0.5 (see Eqs (7)–(9)
and (10)). Here βNN = 0.12, γN = 0.01785, p = 1, d = 0.001, μ = 0.0017, and the initial conditions are SN(0) = 0.999, IN(0)
= 0.001 (see relation (11) for p = 0 and I0 = 0.001).
https://doi.org/10.1371/journal.pone.0220738.g006
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with this study, our model suggests that PRRS KV vaccines can still effectively reduce the
transmission of the infection or eliminate infection from herds by reducing pathogen shedding
and speeding up recovery. Thus, from a purely epidemiological perspective, the results would
imply that KV, if adequately applied could lead to drastic reduction infection prevalence. As
prophylactic vaccination is often avoided in practice in order to reduce the risk of side effects
from vaccination (e.g. vaccination alone may cause low percentages of abortions when used in
breeding herds), timely and targeted reactive vaccination may be the most effective way to mit-
igate PRRS transmission within herds. The large differences in vaccine effectiveness associated
with different vaccination strategies indicate the importance of designing vaccination pro-
grams appropriately as vaccine effectiveness depends largely on the timing and frequency of
vaccination, in addition to the particular vaccines properties.
The model developed in this study is a generic epidemiological SIR model adapted to PRRS
by adopting a large range for the model parameter values from the literature to represent
PRRSv strains of different virulence, different pig populations and different management
structures. This generic modelling approach combined with large parameter ranges was delib-
erately chosen to gain relevant qualitative insight of vaccine and vaccination effects for a wide
scope of scenarios. Obtaining reliable quantitative predictions for specific situations would
require obtaining accurate estimates of the epidemiological model parameters β and γ and the
vaccine effects �s, �i and �γ for existing vaccines; although inferring these from existing data
may be challenging and may require specific experimental designs [43, 52, 55]. Other model
limitations include that specific herd or farm structure, or environmental and management
effects known to influence within-herd transmission dynamics of pathogens (see e.g. [48, 49,
51, 64]), were not explicitly considered in our model. For example, the type of the production
system, the type of animal flow (e.g. continuous vs all-in, all-out) and biosecurity measures, as
well as the spatial proximity to other swine herds and environmental parameters such as aero-
sols, temperature and terrain types (flat vs steep) are established risk factors for PRRS spread
[64–66]. In our model these are only implicitly captured through different R0-values. Further-
more, we only considered horizontal infection transmission in this study, thus ignoring the
potential impact of vaccination on vertical transmission from infected sows or boars to piglets
from the time of insemination during gestation until after birth [25, 67]. In line with the defini-
tion of vaccine effectiveness [68], our model focuses on vaccine effects on reducing disease
invasion and transmission, as reducing the number of infecteds automatically leads to
improved herd health. However, another major aim of PRRSv vaccines is to reduce the impact
of infection on individual health and also on the growth performance in growing piglets or
reproductive failure in pregnant sows [21, 69]. Like most epidemiological models, our model
does not explicitly distinguish between infection and disease, and hence additional parameters
would be required to model the relationship between the prevalence of infection and overall
herd health or productive or reproductive herd performance. Finally, the model developed in
this study considered only transmission of a single wild-type strain in vaccinated populations,
but PRRSv is a diverse quasi-species and different PRRSv strains can circulate simultaneously
in single a herd [70, 71]. The effects of partial protection against single strains are considered
in this model, but the effects of heterogeneous protection against multiple variants simulta-
neously are not included in the present study. This may affect virus evolution and vaccine
safety, and therefore also the predicted long-term effects of vaccination.
In the past, several mathematical models studied the transmission of PRRS in a homoge-
neous population [49, 55, 56], while other studies [43, 48, 51] focused on populations where
vaccination is applied (considered heterogeneous in the sense of vaccination). These studies
provide insight on the evaluation of transmission and recovery from PRRSv infection, and on
the effect of vaccination on epidemic risk and severity. Many of them have a more explicit
Predicting vaccine effectiveness in livestock populations
PLOS ONE | https://doi.org/10.1371/journal.pone.0220738 August 30, 2019 18 / 23
representation of the farm structure with detailed description of the demographics. Building
on simple compartmental models, we performed a comprehensive study of different key
factors that compromise the effectiveness of an incomplete vaccine, where our focus was to
investigate the interactive effects of vaccine properties and vaccination strategies rather than
modelling specific demographic properties. However, the high sensitivity of our model results
on the replacement rate parameters indicate that demographic properties would need to be
adequately represented to achieve high predictive power.
In summary, this study presents a systematic generic modelling framework to investigate
the effectiveness of imperfect vaccines for preventing, mitigating or eliminating infectious dis-
eases in animal populations as a function of vaccine properties, vaccination strategies and
replacement rate of vaccinated and non-vaccinated individuals. The model results suggest that
even imperfect vaccines with no or low levels of sterilizing immunity, or less than 100% effec-
tive coverage, when appropriately applied can prevent, eliminate or largely reduce the preva-
lence of PRRSv and other virus infections, as long as the vaccine sufficiently speeds up
recovery and reduces pathogen shedding. The nearly multiplicative effect of diverse vaccine
properties on the R0 in continuous vaccination highlights the importance of considering the
combined effects of diverse vaccine properties in preventing infection invasion if applied
prophylactically, or in eradicating the infection if applied reactively. In contrast, one-off vacci-
nation with incomplete vaccines only cause a limited short-term reduction in infection preva-
lence, in particular in populations with high replacement rates. Overall, although continuous
prophylactic mass vaccination is the most effective strategy in preventing infection invasion,
one-off reactive vaccination can be more effective when applied at the right time of an ongoing
epidemic than applied one-off prophylactically. The results have practical implications for the
design of vaccines and vaccination programs in livestock populations. In particular, they sug-
gest that in the absence of evolutionary constraints, the control or even elimination of PRRS
through vaccination may well be within reach.
Supporting information
S1 Interactive Modelling App. An interactive app for the model dynamics in the prophy-
lactic vaccination under different replacement rates and different vaccine properties is
available as an R Shiny app from (link). Further details of the model and the interactive app
can be found at this link, which is situated at the University of Edinburgh wiki-server, and out-
lines the components underlying vaccine effectiveness in the field, and their individual and
interactive effects.
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